Skip to content

Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease.

A Prospective Randomized Double Blinded Placebo Controlled Clinical Trial Evaluating the Combined Effect of Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) and Vacuum Erectile Device Combined With Manipulation Exercises on Peyronies Disease.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03530540
Enrollment
50
Registered
2018-05-21
Start date
2018-03-13
Completion date
2020-02-01
Last updated
2019-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peyronie Disease

Brief summary

Aim The primary aim is to examine whether LI-ESWT and vacuum erectile device (VED) followed by manipulation exercises has beneficial effect on PD patients compared to a placebo group. Primary Outcome * Peyronie's Disease Questionnaire (PDQ) * Visual Analogue Scale score (VAS) * International Index of Erectile Function 5 (IEFF-5) * Penile curve measurements (gold standard) on pictures before and after treatment * Plaque size Method This study is designed as a prospective, randomized, double-blinded, placebo-controlled with follow-up after 1, 3 and 6 months. A total of 50 participants who meets the inclusion criteria's will randomly be assigned to I(intervention) or C(control) group based on a randomization list which is retained in a sealed envelope. The content of the envelope is only familiar to the Head of the Department of Urology to ensure valid randomization. All treatment sessions are executed at the outpatient clinic of the department of urology department L at Odense University Hospital(OUH). All patients receive treatment with the same device a Duolith® SD1 T-Top from Storz Medical. However, when treating patients in the control group the handpiece will be covered by a shockwave absorbent material. Settings and setup are identical in both groups to make sure that patients are unable to acknowledge which treatment is being performed.

Interventions

DEVICEPlacebo LI-ESWT

Placebo shockwaves

DEVICEPenile pump

both groups will be treated with a penile pump

Sponsors

Odense University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* PD for more than 6 months * Penile curve greater than 30 degrees and less than 90 degrees * Age 18-80 * No previous penile surgery * Informed consent * Able to speak and understand Danish

Exclusion criteria

* Penile curve greater than 90 degrees * Previous surgery for PD * Patients undergoing other interventions for PD

Design outcomes

Primary

MeasureTime frameDescription
Change in penile curvaturepenile curve will be assessed at baseline, and 1,3 and 6 months.Change in penile curvature from baseline to follow-up at 1,3 and 6 months. Penile curvature is measured on pictures submitted by the patient.

Secondary

MeasureTime frameDescription
Change in pain score using the Visual Analogue Scale (VAS)VAS will be assessed at baseline, and 1,3 and 6 months.VAS is a subjective pain score ranging from 0-10 whereas 0 means no pain, and 10 being excruciating pain. Patients are asked to rank their average pain for the last 24 hours.
Change in Erectile function using the International Index of Erectile Function 5 (IIEF-5).IIEF-5 will be assessed at baseline, and 1,3 and 6 months.Erectile function is estimated using the IIEF-5 which is a 5 item questionnaire. Based on the patients answers a final score is merged. The definition of erectile dysfunction(ED) is; 5-7 (severe), 8-11(moderate), 12-16(mild-moderate), 17-21(mild) and 22-25 no ED.
Change in Peyronies disease questionnaire scorePeyronies disease questionnaire will be assessed at baseline, and 1,3 and 6 months.Questionnaire to evaluate the psychological/physical consequences of peyronies disease.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026